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ABSTRACT 
Background: International travel is increasing, mainly to underdeveloped continents. The 
traveler is a unique pawn in the importation and exportation of endemic diseases. 
Methods: We analyzed 8 years of inpatient data with travel-related disease for demographics, 
travel characteristics and hospitalization outcome. 
Results: 336 inpatients were included, 83% were men. Throughout the years, there was an 
increase of 27% per year of travel-related hospitalizations. African countries were the most 
common destinations, mainly for work-reasons. Expatriates were a major group, representing 
41% of all inpatients, coming mainly from Angola. The main diagnoses were malaria, non-
specified febrile syndrome, and dengue. Malaria (acquired in Africa in 97.1% of the cases) was 
the only with major impact on the need for intensive care, with an estimate of 9 times more 
need than the remaining. Age was a determining factor in hospitalization length (increases) 
and intensive care admission (odds ratio decreases). Four deaths occurred in patients with 
malaria. 
Conclusions: Travel-related illnesses are increasing, and with it the need to anticipate and 
prepare the health system institutions for treatment of such diseases. Efforts should be made 
to improve the preventive care mainly of long term travelers and expatriates, given their 
prolonged exposition and higher risk. 
Keywords: expatriate; travelers; travel medicine; malaria. 
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RESUMO  
Introdução: A viagem internacional está em crescimento, particularmente para países em 
desenvolvimento. O viajante é um peão ímpar na disseminação de doenças.  
Métodos: Neste trabalho foram analisados 8 anos de dados de internamentos de doentes 
adultos com patologia infeciosa de importação, sendo avaliada a evolução demográfica, clínica 
e resultado da hospitalização. 
Resultados: Foram analisados um total de 336 internamentos, 83% do sexo masculino, com 
um aumento de 27%/ano. Os países Africanos que falam português foram os destinos mais 
comuns, maioritariamente por trabalho. Os expatriados representaram 41% dos 
internamentos. Os diagnósticos principais ao longo dos 8 anos foram malária, síndrome febril 
não especificado e dengue. A demora média foi de 9 dias . A malária (adquirida em África em 
97.1% dos casos) teve impacto significativo no internamento em cuidados intensivos e foi 
responsável pelas 4 mortes registadas. A idade foi fator determinante no aumento da duração 
do internamento e na diminuição de admissão em cuidados intensivos. 
Conclusões: É necessário antecipar e preparar as instituições de saúde para o tratamento 
destes doentes. e melhorar o acesso a consultas pré-viagem,  particularmente em viajantes de 
longa estadia e expatriados, dada a sua exposição prolongada e maior risco. 
Palavras-chave: expatriados; viajantes; medicina da viagem; malaria. 
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1. INTRODUCTION 
International travel has become a major component of today’s society. It is responsible for an 
impulse on the socioeconomic progress, job creation and business expansion, and it became 
one of the international sectors with more significant growth in the last 6 decades.[1, 2] 
Despite occasional shocks, tourism has shown virtually uninterrupted growth. International 
tourist arrivals have increased from 25 million globally in 1950, to 278 million in 1980, 527 
million in 1995, and 1133 million in 2014. [1]. Long-distance travel has increased 
disproportionately to shorter courses, especially to countries in Asia and Africa whose 
economical development is rapidly rising.[3, 4] 
There is a multitude of reasons to travel, such as vacations or professional purposes.  In 2014, 
half of the registered travels were on holidays and recreation (53%), with 14% being work-
related and 27% for diverse reasons, such as visiting friends and relatives, humanitarian help, 
and others.  [1] Regardless of that, the burden of disease, mainly of infectious cause, 
associated with trips to countries with different ecosystems and biological threats from the 
origin country are not at all neglectable. This is even more important when considering that 
the journeys to impoverished countries have an increasing importance (in 2010 they 
represented around 50% of the total destinations). [5] Considering these facts, it is not 
surprising that now diseases spread with relative ease, even the ones that were once confined 
to a given region.[5] 
In Portugal with the installation of the economic crisis, there was an increase in the movement 
of individuals for professional reasons, mainly to countries of the European Union (67% of the 
emigrations in 2014), but also to African countries who speak portuguese (ACSP). [6] For these 
reasons, a transformation is being noted in the observed diagnosis in health care, especially in 
the ones dedicated to diagnosis and treatment of infectious diseases.  
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The question we propose to explore is how crisis and globalization changed the demographic 
and the diagnosis of in-patients with a travel-related illness in an Infectious Diseases 
Department (IDD). In order to do so we studied the diagnosis during an 8 years period. IDD is 
integrated in the Centro Hospitalar de São João (CH-SJ), a national reference hospital, in Porto, 
that serves residents, tourists and migrants.  
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2. PATIENTS, MATERIALS AND METHODS 
The patient’s data whose admission was considered related to travel were selected from the 
hard copies and electronic records of the ward of IDD-CHSJ. The study was conducted during 
an 8 year period from January 2007 to December 2014. 
The anonymity was assured through the exclusion of any identification elements.  
The demographic records included: age; sex; birth country; residence country; history of the 
recent travel (length, reason and region); pre-travel medical appointment and prophylaxis, if 
applied; length of the hospital stay in days; inpatient complications; need of intensive care 
(ICU); disease outcome. 
Patients should have a recent travel to or from continental Portugal, and the illness should be 
relatable to the trip. Only the final diagnosis was considered, and cases were included without 
definitive diagnosis, if the importation origin was evident. 
Statistical treatment of data was done through SPSS software. Frequencies, descriptive and 
cross-tabulations procedures [7] were used in view of having a global characterization of 
inpatients and travel behaviors. Significance of patterns and trends were assessed through 
means and proportions comparison tests and linear regressions models [8, 9] 
The main determinants of inpatients diagnosis, need of intensive care and length of stay were 
studied by using convenient regression models. A generalized linear model approach [10, 11] 
was used to fit a Logit model applied in the analysis of ICU (binary data), as well as to fit a 
Poisson regression applied in the analysis of the length of stay (count data). The analysis of 
determinants of inpatients diagnosis (categorical data) was based on a Multinomial Logistic 
Regression. 
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3. RESULTS 
 
3.1. General characteristics of patients hospitalized between 2007 and 2014 
From the 341 inpatients selected according to the inclusion criteria, 5 were excluded due to 
extensive missing data, 336 were included for analysis.  
From the 336 inpatients, 280 were male (83%); differences based on gender were significant1 
and stable2. In the 8 year period of analysis, there was a sustained increase of registered cases 
(figure1.1), corresponding to an average growth rate of 27% per year3. In addition, two 
statistically significant4 outbreaks were registered during the summer of 2009 and spring of 
2013 (figures 1.2 and 1.4). The time series decomposition adjustment (Figure 1.2) reveals the 
absence of significant inpatient seasonality5. 
                                                          
1 t-statistic of 15.04 for the test of equal proportion between men and women, corresponding a p-value 
practically null. 
2 F-statistic of 2.003 for the hypothesis of polynomial trending, corresponding a p-value of 0.226. 
3 Based on an exponential trending regression with a F-statistic of 9.160, corresponding a p-value of 
0.023 
4 An estimate of 30 additional inpatients were registered in 2009 and 2013 with a t-statistic of 9.746 and 
p-value practically null. 
5 F-statistic of 2.264 for the hypothesis of non-significant seasonality, corresponding a p-value practically 
null. 
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Figure 1 - Inpatients and hospitalization trends 
  
  
The growth tendency of inpatients with imported disease (figure 1.3) is fundamentally 
associated with malaria, dengue fever (DF) and non-specified febrile syndrome (NSFS) 
diagnosis. The two peaks of 2009 and 2013 were associated with outbreaks of importation 
illnesses. In 2009, there was an important increase of NSFS (39% of patients), but also of 
influenza A infection (20.3%). In 2013, a significant incidence of malaria cases (43%), and DF 
(30.1%) was registered. In 2014, the number of inpatients was highly determined by malaria 
(63.1%).  
Table 1 shows information of inpatients according to diagnosis, average age and hospital stay 
length and ICU cases. The most common diagnoses were malaria (51.9%), NSFS (16%) and DF 
(11.3%). The remaining illnesses (others, 20.8%) included influenza A infection, traveler’s 
diarrhea, respiratory infection, among others.  
The average age of inpatients sample was 41 years, being identical for the average age of the 
most frequent diseases. The diagnoses with higher average ages were other systemic viral 
infections (73 years), DF co-infected with HIV (59 years) and infectious arthropathy (55 years). 
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Among the diseases with the lowest average age are traveler’s diarrhea (28 years) and typhoid 
fever (27 years). 
 Table 1 – Registered diagnosis in the period of January 2007 to December 2014 
Diagnosis Patients Hospital Deaths N % Age Days ICU 
Malaria 175 51.9 42 9 63 4 
Non-specifed febrile syndrome 54 16.0 41 5 1  
Dengue fever 38 11.3 40 4   
Influenza A infection 12 3.6 40 3 1  
Traveler’s diarrhea  10 3.0 28 8   
Respiratory infection 9 2.7 54 7 1  
Skin/subcutaneous infection 6 1.8 42 7   
Hepatic/Renal abscess 4 1.2 38 15   
Malaria & HIV coinfection 4 1.2 45 29 3  
Clear cerebrospinal fluid (CSF) meningitis 4 1.2 34 5   
HIV infection (new diagnosis) 4 1.2 49 15   
Other sexually transmited diseases 2 0.6 45 8   
Malaria & Dengue coinfection 2 0.6 37 6   
Chronic osteomyelitis 2 0.6 22 18   
Trypanosomiasis 2 0.6 42 28   
Infectious artropathy 1 0.3 55 3   
Dengue fever & HIV coinfection 1 0.3 59 14   
Chikungunya fever 1 0.3 41 4   
Typhoid fever 1 0.3 27 6   
Hepatitis A 1 0.3 35 6   
Other systemic viral infections 1 0.3 73 54   
Rubeola 1 0.3 49 3   
Measls 1 0.3 35 6   
Total 336 100 41 9 69 4 
On average, inpatients had a hospital stay of 9 days. The most frequent diseases had an equal 
or shorter average stay: malaria (9 days), NSFS (5 days) and DF (4 days). Patients who had HIV 
co-infection had an increased length of stay to 29 for malaria and 14 days for DF. The 
diagnoses associated with longer hospital stays (and 4 or more cases) were other viral systemic 
infections (54 days) and Hepatic/Renal abscess (15 days). 20.5% of inpatients were admitted in 
the ICU (most with malaria). Four deaths were registered, all in patients with malaria (malaria 
fatality rate 2.2%). 
Table 2 crosses most relevant residence countries with travel destinations. Destinations 
include countries from all continents, with a highlight to Portuguese-speaking African countries 
(50.7% of total destinations), namely Angola (38.5%).Portugal was the main residence country 
(47.9%), followed by Angola (33.3%).  
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Most inpatients were residents abroad: expatriates (41%) and 8% foreign travelers visiting 
Portugal (figure 2.3). Travelers with shorter stays (less than a month) represent 32% of 
inpatients; the travelers for periods of 1 to 6 months correspond to 14% and for longer periods 
(>6 months) 5% of cases. 
Table 2 - Inpatients per country of residence and of travel destinations 
Residence 
country 
Countries from/to the patient traveled 
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Angola 112          112 
Brazil  5         5 
Spain   4        4 
USA    5       5 
France   2  2     1 5 
Guinea      5     5 
UK   1    2   1 4 
Mozambique        15   15 
Portugal 62 11 16 1 2 4  14 1 50 161 
Others    1 1     18 20 
Total 174 16 23 7 5 9 2 29 1 70 336 
Along the years, a trend growth of inpatients coming from Africa, and fundamentally from 
Angola, is visible with a peak on the year of 2013 (figure 2.1). In 2009 there was a peak of 
patients traveling in Europe, mainly from Spain. 
Most travels were work-related (74.2%), and for holidays (19.3%) (figure 2.2). Throughout the 
period of analysis, the number of inpatients having travelled for work reasons was the one 
which grew the most. The outbreak registered in 2009 is associated with tourism and work 
related travels, the outbreak in 2013 is mainly associated with work-related trips. 
As for pre-travel preventive care (figure 2.4), information was available in 222 from the 285 
patients who should have had a pre-travel consultation. From these 222 travelers, 58.6% got a 
pre-travel medical appointment and 38.3% did not have medical advice. 
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Figure 2 - Inpatients travel patterns – tourism, work, others 
  
  
3.2. Pattern and determinants of diagnosis and hospitalization 
The explicative model of diagnosis aims to differentiate the behavior of the most frequent 
diseases: malaria, dengue fever and NSFS, comparing them to the remaining diagnoses 
(reference category). This analysis was performed in relation to the two most important 
epidemiologic factors: origin region and season. Factors such as age or sex revealed as non 
significant. 
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Table 3 - Multinomial Logistic Regressions of Diagnosis  
Covariates 
Chi-square 
likelihood 
ratio 
Dengue fever Malaria NSFS 
Significance Odds ratio Significance Odds ratio Significance Odds ratio 
Season 
Spring Statistic 
201,811 
Significance 
0,000 
0.042 1.875 0.000 3.812 0.451 0.750 
Summer 0.000 0.207 0.896 1.034 0.896 1.034 
Autumn 0.067 0.300 0.000 4.400 0.638 0.800 
Winter 0.069 0.143 0.000 6.286 0.372 0.571 
Region 
Angola 
Statistic 
310,654 
Significance 
0,000 
0.074 1.750 0.000 7.437 0.715 0.875 
Guinea - 0.000 0.050 8.000 - 0.000 
Mozambique 0.997 0.000 0.001 8.000 0.657 0.667 
Others Africa 0.997 0.000 0.001 7.667 0.484 1.667 
Brazil 0.410 0.625 0.080 0.250 0.080 0.250 
Others Americas 0.147 0.375 0.080 0.250 0.796 0.875 
Asia & Oceania 0.220 0.429 0.997 0.000 0.220 0.429 
Europe 0.007 0.063 0.007 0.063 0.413 1.313 
According to the analysis, dengue and malaria differ significantly from all other diseases in 
both factors, the origin region and the season. NSFS behavior was not statistically different 
from the other diseases (reference category) when considering the season. In relation to the 
region of travel we may say that the only significant difference refers to Brazil, where, with 8% 
significance, it is less likely for a patient travelling from that destination to be a diagnosed with 
NSFS (4 times less likely).   
Dengue occurred relatively more frequently in the spring, and less frequently in the other 
seasons (particularly in the summer). The estimate of the probability for dengue to occur is 
almost twice the probability of another disease during spring (except malaria) occurring, and 5 
times less in summer than the reference category. When comparing the region of travel, the 
differentiation is significant for Angola and Europe. We can estimate, with a relatively low level 
of significance (7.4%), that a patient returning from Angola has almost twice the probability of 
a dengue infection, than other diseases (except malaria).  
Malaria occurs relatively more during the spring, autumn and winter months, with no 
significant difference detected in the summer. During the spring and autumn, the probability 
of an occurrence of malaria is 4 times more likely than another diagnosis (except dengue); in 
winter it is 6 times more likely. Regarding the region of origin, the entire African continent was 
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significant, for which it is estimated that the probability of malaria is 8 times that of all other 
diseases (except dengue).  
The explanatory models applied in the analysis of ICU (Logit model) and length of hospital stay 
(Poisson model) include as relevant impact factors age (years), diagnosis (reference category is 
other diseases) and existence of complications. Both models are globally significant and all 
explanatory factors are individually significant, except on what concerns the impact of dengue 
and NSFS on the need of intensive care.  
Table 4 – Regression analysis of inpatient stays 
Model Logit model Log-linear Poisson model 
Dependent variable Intensive care unit Length of stay 
Chi-square 
likelihood ratio 
Statistic 217.791 742.506 
Significance 0.000 0.000 
Covariates Significance Odds ratio Significance Growth index 
Constant 0,017 0.043 0.000 5.716 
Age 0,035 0.948 0.000 1.007 
Diagnosis 
Dengue fever 0.998 0.000 0.000 0,463 
Malaria 0.009 9.349 0.000 0,748 
NSFS 0.689 1.754 0.000 0,617 
Existence of complications  0,000 136.469 0.000 2.619 
The age was a significantly determinant factor for the duration of the hospital stay and for the 
ICU admission. The length of the stay increases with age (with an estimate growth of 0.7% for 
each additional year), the odds ratio estimate of patients that need ICU in relation to those not 
requiring it decreases with age.  
Nosocomial infections and organ dysfunction were the main determinants of the length of stay 
and of the need of intensive care admission; in these cases, the length of stay is expected to 
increase, in average, 160%, and the need of intensive care is expected to increase to a 
proportion of 136 times. 
Malaria was the only diagnosis with major impact on the need for intensive care, being 
estimated that, compared to all other diseases, a patient with malaria is 9 times more likely to 
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need intensive care. The length of stay is inferior in patients with dengue, malaria and NSFS. 
Compared to other diseases (reference category), in average, it is estimated that these 
patients have, respectively, a length of stay inferior in 53.7%, 25.2% and 38.3%. 
3.3. REVIEW OF MAIN DIAGNOSIS 
3.3.1. Malaria (53.1%) 
There were 181 cases of malaria, 4 co-infected with HIV, 2 with dengue. 159 were men. 87.2% 
of cases were within the range of 25-54 years. Plasmodium falciparum was identified in 131 
patients; the remainders were mixed infection (P. falciparum and other; 8 patients), P. 
malariae (3 patients), P. ovale (3 patients) and P. vivax (3 patients). In 31 patients it was not 
possible to identify the species. 
Malaria was acquired in Africa in 97.1% of the cases, being 83.3% of the cases from PSAC 
[Angola (65.5%), Mozambique (13.2%) and Guinea (4.6%)]; 2.9% of malaria cases were from   
south-America countries. Most patients were living in Portugal (44.1%) and Angola (39 %), the 
majority were Portuguese (80%). The travel was chiefly due to work (85%). The 4 patients with 
malaria and inaugural HIV diagnosis were expatriate travelers from Angola (3 cases) and 
Mozambique (1 case).  
Two patients (0.6%) diagnosed with both malaria and dengue fever were men who came from 
Angola.  
The hospital stay was 4-10 days in most cases (63%). There were some severe cases of malaria: 
10 had ARDS (Adult Respiratory Distress Syndrome) and 13 had multiple organ failure (MOF). 
Most had a favorable outcome; 4 deaths were registered in patients with ARDS, neurologic 
dysfunction and MOF. 
Only 29 patients declared having fulfilled the recommended prevention. 
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3.3.2. Non-specified febrile syndrome (16%) 
The febrile illness was cause of admission of 54 patients, 40 of which were men. A big 
percentage of cases was during 2009 (42.6%) (figure 6). Most patients were 30 to 44 years old 
(52%).  24% patients returned from Angola and 24% from Spain, most of which lived in 
Portugal (61.1%). The most common reason declared was business (65%). 55% patients had a 
hospital stay of 3 days or less.  
3.3.3. Dengue fever (11.6%) 
Dengue fever was responsible for 39 admissions (84.6% were men). There was an 
augmentation of the number of cases throughout the years, with a peak in 2013 (figure 1.3). 1 
patient had previously known HIV infection. These patients were 25-49 years old (73.7%); 84% 
were of Portuguese nationality. 
These cases were mainly imported from Angola (68.4%) and Brazil (13.2%). There were cases 
reported from other south-american countries, Asia, Oceania, and one case of a patient 
resident in Madeira island. Mostly, these patients lived in Angola (53.8%) and Portugal (43.6%). 
DF was associated with tourism in only 9 patients (11%).  
Most patients had a hospital stay of 4 to 10 days (64.5%).  All patients had a good evolution, 
and no patient required intensive care. 
3.3.4. Others (20.8%) 
All less frequent diagnoses were included in this group. The diagnosis included influenza A 
infection (12 cases – 3.6%), traveler’s diarrhea (10 cases – 3%), respiratory infection (9 cases – 
2.7%), among others (table 1). Emphasis is given to influenza A infection, with 12 confirmed 
cases during the year of 2009. These patients had traveled to Spain (41.7%), Brazil (16.7%) and 
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other south-american countries (16.7%). In some cases the origin of the infection was difficult 
to track because of multi-destinations.  
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4. DISCUSSION 
The biggest evidence shown in this work was the obvious and important increase of 
importation diseases along the analyzed years. This augmentation pattern is expected to 
continue, attending to the tendency of growth of international tourism, as well as migratory 
flows. This develops the need of controlling the associated health issues. [12] 
When comparing with international literature, namely GeoSentinel studies, it was notorious 
the existence of a difference in the infectious patterns of the European travelers. [13] This is 
due to a complex migratory network, inside and outside of Europe, with a bigger relative 
number of travels to endemic areas, such as Africa. Besides that, even when evaluated with 
the European pattern, on EuroTravNet studies [13], the Portuguese movements have a larger 
proportion of African destinations, of 73.5%, against 32% reported in such studies. 
The reason for travel also had a substantial disparity. In most works, tourism was associated 
with most travels, contrarily to these results. [2-4, 13, 14] However, this is probably due to 
several reasons, namely inclusion of inpatients only, and the fact that expatriates are more 
exposed to prolonged stays, endemic countries and worse living conditions. Despite this 
limitation, we can conclude that among pathologies that require hospital treatment, work-
travel has a bigger weight than tourism-travel.  
A smashing majority of men among the returning ill travelers (83%) was reported. It has been 
reported that men travel more than women, and that they predominate in business travel. 
[15] This may add to differences in exposures, activities with higher risk and use of preventive 
strategies. Men usually have long stays and outside work-related activities that augment their 
risk of infection. Several previous studies also shown that men are more likely to contract 
malaria.[16-18] Besides the environmental risks, it has been suggested that there are biological 
factors that increase male susceptibility to mosquito-borne infections.[15] 
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The transmission of malaria, particularly in sub-Saharan Africa, is intimately related to the 
rainy season, when rainfall and warm temperatures coexist, creating conditions to the spread 
of malaria. [19-22] Angola, belonging to this region, has a higher frequency of patients with 
this diagnosis during the rainy months. Given that the incubation time for P. falciparum is 8 to 
14 days, in non-immune people [23], the demonstration of the econometric data reflects this 
seasonal relation.  
Along the period of analysis, two main clusters were observed. The first, in 2009, was 
associated with the influenza pandemic. [2] International travelers were individuals at risk 
when their trip involved affect areas. [24] The pandemic peak was during August of 2009. [25] 
This was consistent with the majority of cases reported in our study (of the 12 confirmed 
influenza A infections, 10 were returning of vacations during the summer months). Associated 
with this infection, a different destination trend was registered, with a highlight to Spain, 
country that acquired an important role during that year. It is important to notice that a peak 
of inpatients for NSFS was registered during the H1N1 pandemic (figure 1.3). The increase of 
febrile illness during 2009 could reflect an increased attention and fear of the circulating virus, 
and a real increase in disease acquisition among traveling individuals.[24] It is also possible 
that some cases may have corresponded to influenza A infection whose agent was not 
identified. 
In 2013, an outbreak of dengue took place in Angola [26, 27]; it was reported by local health 
authorities in April 2013.[28] An increase of the number of inpatients with DF corresponded to 
Portuguese individuals emigrants in Angola, coming to Portugal to get treatment. Besides that, 
the augment registered along the years 2013 and 2014 was not only due to the dengue 
outbreak, but also by the increasing trend of admittances by travel-related illnesses, 
specifically malaria.  
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Given the morbidity of travel-related illnesses, it is important to reflect about the promotion of 
preventive behaviors and pre-travel advice relevance on the population intending to travel to 
endemic areas of infectious diseases, such as the African continent. A significant percentage of 
patients abandoned early, or never initiated, the recommended chemoprophylaxis for malaria, 
although some of them, due to several years of stay in endemic area, were not considered for 
receiving chemoprevention. Repellents and bed nets should be remembered as important 
mechanisms of protection from arthropods transmitted diseases during all stay in endemic 
areas.[29] It is of higher importance to invest on traveler’s information, discuss the advantages 
associated with adherence to medical advices, provide practical advices [30], and increase the 
number of travelers who attend a pre-travel appointment[4], preferably 4 to 6 weeks before 
traveling. [31] 
5. CONCLUSIONS 
The most striking evidences of the work were the significant increase of importation diseases 
(27% per year), with a clear majority of male patients. It is also interesting to observe the 
dominance of work-related trips, predominantly to Angola, explaining the majority of malaria 
diagnosis (highly endemic area, longer stays, exposition risk augmentation, lack of preventive 
measurements).  Having this characterization of the dynamic nature of importation diseases, 
namely the current increase registered, hospital services can anticipate and prepare to receive 
and adequately treat patients with these diagnoses. It would be also important to improve 
preventive care, given the small percentage of patients who kept the adequate 
recommendations.  
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6. LIMITATIONS 
We only included inpatients, making it not possible to compare with patients with travel-
related illnesses that did not fulfill hospitalization criteria. This leads to an overestimation of 
more serious diseases, and underestimation of other diagnoses, such as gastrointestinal 
disturbances or sexually transmissible diseases or dermatologic manifestations, among others. 
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Copyright
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more information on this and copyright, see https://www.elsevier.com/copyright). An e-mail will
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Author rights
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information see https://www.elsevier.com/copyright.
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for associated publication fees. To learn more about existing agreements please visit
https://www.elsevier.com/fundingbodies.
After acceptance, open access papers will be published under a noncommercial license. For authors
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Open access
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or institution
Subscription
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our universal access programs (https://www.elsevier.com/access).
• No open access publication fee payable by authors.
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Elsevier's pricing policy: http://www.elsevier.com/openaccesspricing.
Green open access
Authors can share their research in a variety of different ways and Elsevier has a number of green
open access options available. We recommend authors see our green open access page for further
information (http://elsevier.com/greenopenaccess). Authors can also self-archive their manuscripts
immediately and enable public access from their institution's repository after an embargo period. This
is the version that has been accepted for publication and which typically includes author-incorporated
changes suggested during submission, peer review and in editor-author communications. Embargo
period: For subscription articles, an appropriate amount of time is needed for journals to deliver
value to subscribing customers before an article becomes freely available to the public. This is the
embargo period and it begins from the date the article is formally published online in its final and
fully citable form.
This journal has an embargo period of 12 months.
Language (usage and editing services)
Please write your text in good English (American or British usage is accepted, but not a
mixture of these). Authors who feel their English language manuscript may require editing
to eliminate possible grammatical or spelling errors and to conform to correct scientific
English may wish to use the English Language Editing service available from Elsevier's
WebShop (http://webshop.elsevier.com/languageediting/) or visit our customer support site
(http://support.elsevier.com) for more information.
Informed consent and patient details
Studies on patients or volunteers require ethics committee approval and informed consent, which
should be documented in the paper. Appropriate consents, permissions and releases must be obtained
where an author wishes to include case details or other personal information or images of patients and
any other individuals in an Elsevier publication. Written consents must be retained by the author and
copies of the consents or evidence that such consents have been obtained must be provided to Elsevier
on request. For more information, please review the Elsevier Policy on the Use of Images or Personal
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Information of Patients or other Individuals, https://www.elsevier.com/patient-consent-policy. Unless
you have written permission from the patient (or, where applicable, the next of kin), the personal
details of any patient included in any part of the article and in any supplementary materials (including
all illustrations and videos) must be removed before submission.
Submission
Our online submission system guides you stepwise through the process of entering your article
details and uploading your files. The system converts your article files to a single PDF file used in
the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for
final publication. All correspondence, including notification of the Editor's decision and requests for
revision, is sent by e-mail.
Submit your article
Please submit your article via http://ees.elsevier.com/tmaid/default.asp.
Referees
Please submit the names and institutional e-mail addresses of several potential referees. For more
details, visit our Support site. Note that the editor retains the sole right to decide whether or not the
suggested reviewers are used.
PREPARATION
Subdivision - numbered sections
Divide your article into clearly defined and numbered sections. Subsections should be numbered
1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this
numbering also for internal cross-referencing: do not just refer to 'the text'. Any subsection may be
given a brief heading. Each heading should appear on its own separate line.
Introduction
State the objectives of the work and provide an adequate background, avoiding a detailed literature
survey or a summary of the results.
Material and methods
Provide sufficient detail to allow the work to be reproduced. Methods already published should be
indicated by a reference: only relevant modifications should be described.
Experimental
Provide sufficient detail to allow the work to be reproduced. Methods already published should be
indicated by a reference: only relevant modifications should be described.
Theory/calculation
A Theory section should extend, not repeat, the background to the article already dealt with in the
Introduction and lay the foundation for further work. In contrast, a Calculation section represents a
practical development from a theoretical basis.
Results
Results should be clear and concise.
Discussion
This should explore the significance of the results of the work, not repeat them. A combined Results
and Discussion section is often appropriate. Avoid extensive citations and discussion of published
literature.
Conclusions
The main conclusions of the study may be presented in a short Conclusions section, which may stand
alone or form a subsection of a Discussion or Results and Discussion section.
Appendices
If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in
appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix,
Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.
Essential title page information
• Title. Concise and informative. Titles are often used in information-retrieval systems. Avoid
abbreviations and formulae where possible.
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Abstract
Original articles should include a structured abstract of no more than 200 words. In original articles,
the Abstract should consist of 4 paragraphs, labelled Background, Method, Results, Conclusions. They
should briefly describe the problems being addressed in the study, how the study was performed
and which measurements were carried out, the most relevant results, and what the authors conclude
from the results. A recent copy of the journal should be consulted as a guide. An abstract is often
presented separate from the article, so it must be able to stand alone.
Keywords
Authors should provide a list of 3 - 6 keywords (not used in the title) on the first page of the
manuscript, avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of').
Use terms form the Medical Subject headings from the Index Medicus. Be sparing with abbreviations:
only abbreviations firmly established in the field may be eligible. These keywords will be used for
indexing purposes.
Abbreviations
Define abbreviations that are not standard in this field in a footnote to be placed on the first page
of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first
mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.
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Units
Follow internationally accepted rules and conventions: use the international system of units (SI). If
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Artwork
Image manipulation
Whilst it is accepted that authors sometimes need to manipulate images for clarity, manipulation for
purposes of deception or fraud will be seen as scientific ethical abuse and will be dealt with accordingly.
For graphical images, this journal is applying the following policy: no specific feature within an image
may be enhanced, obscured, moved, removed, or introduced. Adjustments of brightness, contrast,
or color balance are acceptable if and as long as they do not obscure or eliminate any information
present in the original. Nonlinear adjustments (e.g. changes to gamma settings) must be disclosed
in the figure legend.
Electronic artwork
General points
• Make sure you use uniform lettering and sizing of your original artwork.
• Embed the used fonts if the application provides that option.
• Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or
use fonts that look similar.
• Number the illustrations according to their sequence in the text.
• Use a logical naming convention for your artwork files.
• Provide captions to illustrations separately.
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• Size the illustrations close to the desired dimensions of the published version.
• Submit each illustration as a separate file.
A detailed guide on electronic artwork is available on our website:
https://www.elsevier.com/artworkinstructions.
You are urged to visit this site; some excerpts from the detailed information are given here.
Formats
If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then
please supply 'as is' in the native document format.
Regardless of the application used other than Microsoft Office, when your electronic artwork is
finalized, please 'Save as' or convert the images to one of the following formats (note the resolution
requirements for line drawings, halftones, and line/halftone combinations given below):
EPS (or PDF): Vector drawings, embed all used fonts.
TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.
TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.
TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of
500 dpi.
Please do not:
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a
low number of pixels and limited set of colors;
• Supply files that are too low in resolution;
• Submit graphics that are disproportionately large for the content.
Color artwork
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or
MS Office files) and with the correct resolution. If, together with your accepted article, you submit
usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear
in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations
are reproduced in color in the printed version. For color reproduction in print, you will receive
information regarding the costs from Elsevier after receipt of your accepted article. Please
indicate your preference for color: in print or online only. For further information on the preparation
of electronic artwork, please see https://www.elsevier.com/artworkinstructions.
Illustration services
Elsevier's WebShop (http://webshop.elsevier.com/illustrationservices) offers Illustration Services
to authors preparing to submit a manuscript but concerned about the quality of the images
accompanying their article. Elsevier's expert illustrators can produce scientific, technical and medical-
style images, as well as a full range of charts, tables and graphs. Image 'polishing' is also available,
where our illustrators take your image(s) and improve them to a professional standard. Please visit
the website to find out more.
Figure captions
Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A
caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep
text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.
Tables
Please submit tables as editable text and not as images. Tables can be placed either next to the
relevant text in the article, or on separate page(s) at the end. Number tables consecutively in
accordance with their appearance in the text and place any table notes below the table body. Be
sparing in the use of tables and ensure that the data presented in them do not duplicate results
described elsewhere in the article. Please avoid using vertical rules.
References
Citation in text
Please ensure that every reference cited in the text is also present in the reference list (and vice
versa). Any references cited in the abstract must be given in full. Unpublished results and personal
communications are not recommended in the reference list, but may be mentioned in the text. If these
references are included in the reference list they should follow the standard reference style of the
journal and should include a substitution of the publication date with either 'Unpublished results' or
'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted
for publication.
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Reference links
Increased discoverability of research and high quality peer review are ensured by online links to
the sources cited. In order to allow us to create links to abstracting and indexing services, such as
Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please
note that incorrect surnames, journal/book titles, publication year and pagination may prevent link
creation. When copying references, please be careful as they may already contain errors. Use of the
DOI is encouraged.
Web references
As a minimum, the full URL should be given and the date when the reference was last accessed. Any
further information, if known (DOI, author names, dates, reference to a source publication, etc.),
should also be given. Web references can be listed separately (e.g., after the reference list) under a
different heading if desired, or can be included in the reference list.
References in a special issue
Please ensure that the words 'this issue' are added to any references in the list (and any citations in
the text) to other articles in the same Special Issue.
Reference management software
Most Elsevier journals have their reference template available in many of the
most popular reference management software products. These include all products
that support Citation Style Language styles (http://citationstyles.org), such as Mendeley
(http://www.mendeley.com/features/reference-manager) and Zotero (https://www.zotero.org/), as
well as EndNote (http://endnote.com/downloads/styles). Using the word processor plug-ins from
these products, authors only need to select the appropriate journal template when preparing their
article, after which citations and bibliographies will be automatically formatted in the journal's style.
If no template is yet available for this journal, please follow the format of the sample references and
citations as shown in this Guide.
Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following
link:
http://open.mendeley.com/use-citation-style/travel-medicine-and-infectious-disease
When preparing your manuscript, you will then be able to select this style using the Mendeley plug-
ins for Microsoft Word or LibreOffice.
Reference style
Text: Indicate references by number(s) in square brackets in line with the text. The actual authors
can be referred to, but the reference number(s) must always be given.
Example: '..... as demonstrated [3,6]. Barnaby and Jones [8] obtained a different result ....'
List: Number the references (numbers in square brackets) in the list in the order in which they appear
in the text.
Examples:
Reference to a journal publication:
[1] J. van der Geer, J.A.J. Hanraads, R.A. Lupton, The art of writing a scientific article, J. Sci. Commun.
163 (2010) 51–59.
Reference to a book:
[2] W. Strunk Jr., E.B. White, The Elements of Style, fourth ed., Longman, New York, 2000.
Reference to a chapter in an edited book:
[3] G.R. Mettam, L.B. Adams, How to prepare an electronic version of your article, in: B.S. Jones, R.Z.
Smith (Eds.), Introduction to the Electronic Age, E-Publishing Inc., New York, 2009, pp. 281–304.
Reference to a website:
[4] Cancer Research UK, Cancer statistics reports for the UK. http://www.cancerresearchuk.org/
aboutcancer/statistics/cancerstatsreport/, 2003 (accessed 13.03.03).
Journal abbreviations source
Journal names should be abbreviated according to the List of Title Word Abbreviations:
http://www.issn.org/services/online-services/access-to-the-ltwa/.
Video data
Elsevier accepts video material and animation sequences to support and enhance your scientific
research. Authors who have video or animation files that they wish to submit with their article are
strongly encouraged to include links to these within the body of the article. This can be done in the
same way as a figure or table by referring to the video or animation content and noting in the body
text where it should be placed. All submitted files should be properly labeled so that they directly
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relate to the video file's content. In order to ensure that your video or animation material is directly
usable, please provide the files in one of our recommended file formats with a preferred maximum
size of 150 MB. Video and animation files supplied will be published online in the electronic version
of your article in Elsevier Web products, including ScienceDirect: http://www.sciencedirect.com.
Please supply 'stills' with your files: you can choose any frame from the video or animation or
make a separate image. These will be used instead of standard icons and will personalize the
link to your video data. For more detailed instructions please visit our video instruction pages at
https://www.elsevier.com/artworkinstructions. Note: since video and animation cannot be embedded
in the print version of the journal, please provide text for both the electronic and the print version
for the portions of the article that refer to this content.
Supplementary material
Supplementary material can support and enhance your scientific research. Supplementary files
offer the author additional possibilities to publish supporting applications, high-resolution images,
background datasets, sound clips and more. Please note that such items are published online exactly
as they are submitted; there is no typesetting involved (supplementary data supplied as an Excel
file or as a PowerPoint slide will appear as such online). Please submit the material together with the
article and supply a concise and descriptive caption for each file. If you wish to make any changes to
supplementary data during any stage of the process, then please make sure to provide an updated
file, and do not annotate any corrections on a previous version. Please also make sure to switch
off the 'Track Changes' option in any Microsoft Office files as these will appear in the published
supplementary file(s). For more detailed instructions please visit our artwork instruction pages at
https://www.elsevier.com/artworkinstructions.
Submission checklist
The following list will be useful during the final checking of an article prior to sending it to the journal
for review. Please consult this Guide for Authors for further details of any item.
Ensure that the following items are present:
One author has been designated as the corresponding author with contact details:
• E-mail address
• Full postal address
All necessary files have been uploaded, and contain:
• Keywords
• All figure captions
• All tables (including title, description, footnotes)
Further considerations
• Manuscript has been 'spell-checked' and 'grammar-checked'
• References are in the correct format for this journal
• All references mentioned in the Reference list are cited in the text, and vice versa
• Permission has been obtained for use of copyrighted material from other sources (including the
Internet)
Printed version of figures (if applicable) in color or black-and-white
• Indicate clearly whether or not color or black-and-white in print is required.
For any further information please visit our customer support site at http://support.elsevier.com.
AFTER ACCEPTANCE
Use of the Digital Object Identifier
The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI
consists of a unique alpha-numeric character string which is assigned to a document by the publisher
upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal
medium for citing a document, particularly 'Articles in press' because they have not yet received their
full bibliographic information. Example of a correctly given DOI (in URL format; here an article in the
journal Physics Letters B):
http://dx.doi.org/10.1016/j.physletb.2010.09.059
When you use a DOI to create links to documents on the web, the DOIs are guaranteed never to
change.
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Online proof correction
Corresponding authors will receive an e-mail with a link to our online proofing system, allowing
annotation and correction of proofs online. The environment is similar to MS Word: in addition to
editing text, you can also comment on figures/tables and answer questions from the Copy Editor.
Web-based proofing provides a faster and less error-prone process by allowing you to directly type
your corrections, eliminating the potential introduction of errors.
If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions
for proofing will be given in the e-mail we send to authors, including alternative methods to the online
version and PDF.
We will do everything possible to get your article published quickly and accurately. Please use this
proof only for checking the typesetting, editing, completeness and correctness of the text, tables and
figures. Significant changes to the article as accepted for publication will only be considered at this
stage with permission from the Editor. It is important to ensure that all corrections are sent back
to us in one communication. Please check carefully before replying, as inclusion of any subsequent
corrections cannot be guaranteed. Proofreading is solely your responsibility.
Offprints
The corresponding author, at no cost, will be provided with a personalized link providing 50
days free access to the final published version of the article on ScienceDirect. This link can
also be used for sharing via email and social networks. For an extra charge, paper offprints
can be ordered via the offprint order form which is sent once the article is accepted for
publication. Both corresponding and co-authors may order offprints at any time via Elsevier's
WebShop (http://webshop.elsevier.com/myarticleservices/offprints). Authors requiring printed copies
of multiple articles may use Elsevier WebShop's 'Create Your Own Book' service to collate multiple
articles within a single cover (http://webshop.elsevier.com/myarticleservices/booklets).
AUTHOR INQUIRIES
You can track your submitted article at https://www.elsevier.com/track-submission. You can track
your accepted article at https://www.elsevier.com/trackarticle. You are also welcome to contact
Customer Support via http://support.elsevier.com.
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